Protagenic Therapeutics (NASDAQ:PTIX) — Market Cap & Net Worth
Market Cap & Net Worth: Protagenic Therapeutics (PTIX)
Protagenic Therapeutics (NASDAQ:PTIX) has a market capitalization of $1.43 Million ($1.43 Million) as of October 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #30432 globally and #6209 in its home market, demonstrating a -17.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Protagenic Therapeutics's stock price $0.83 by its total outstanding shares 1810208 (1.81 Million).
Protagenic Therapeutics Market Cap History: 2015 to 2026
Protagenic Therapeutics's market capitalization history from 2015 to 2026. Data shows change from $22.39 Million to $1.50 Million (-31.25% CAGR). Check current stock price of Protagenic Therapeutics for real-time trading data and today's change.
Index Memberships
Protagenic Therapeutics is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.59 Trillion | 0.00% | #889 of 976 |
|
NASDAQ Composite
IXIC
|
$42.02 Trillion | 0.00% | #2829 of 3165 |
Weight: Protagenic Therapeutics's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Protagenic Therapeutics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Protagenic Therapeutics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see PTIX cash generation efficiency for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of PTIX by Market Capitalization
Companies near Protagenic Therapeutics in the global market cap rankings as of October 16, 2026. See debt-free asset ratio of Protagenic Therapeutics to understand what proportion of total assets are financed by equity.
Key companies related to Protagenic Therapeutics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #190 globally with a market cap of $126.35 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #365 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #443 globally with a market cap of $63.37 Billion USD ( AU$89.55 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #507 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #190 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $126.35 Billion | $498.50 |
| #365 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $778.36 |
| #443 | CSL Ltd | AU:CSL | $63.37 Billion | AU$184.59 |
| #507 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $226.30 |
Protagenic Therapeutics Historical Marketcap From 2015 to 2026
Between 2015 and today, Protagenic Therapeutics's market cap moved from $22.39 Million to $ 1.50 Million, with a yearly change of -31.25%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.50 Million | -36.15% |
| 2025 | $2.35 Million | +165.31% |
| 2024 | $887.00K | -50.51% |
| 2023 | $1.79 Million | -38.12% |
| 2022 | $2.90 Million | -71.12% |
| 2021 | $10.03 Million | +31.90% |
| 2020 | $7.60 Million | -25.54% |
| 2019 | $10.21 Million | -29.50% |
| 2018 | $14.48 Million | -9.09% |
| 2017 | $15.93 Million | -71.55% |
| 2016 | $55.99 Million | +150.00% |
| 2015 | $22.39 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 15th, 2026 the market cap of Protagenic Therapeutics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.43 Million USD |
| MoneyControl | $1.43 Million USD |
| MarketWatch | $1.43 Million USD |
| marketcap.company | $1.43 Million USD |
| Reuters | $1.43 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Protagenic Therapeutics
Protagenic Therapeutics, Inc. operates as a pharmaceutical company specializing in the development of medicines manufactured from cannabinoid and cannabinoid-like molecules. Protagenic Therapeutics, Inc. was founded in 2004 and is based in Santa Barbara, California.